Form 4: Heartflow Director Acquires Stock Options

Heartflow, Inc. director Wayne Joseph Riley acquired 16,075 stock options at an exercise price of $32.05, with vesting scheduled for 2027.

Summary

• Wayne Joseph Riley, a Director at Heartflow, Inc., acquired 16,075 stock options on June 16, 2026.
• The exercise price for these options is $32.05 per share.
• The options are set to vest in full on the earlier of the day before Heartflow's 2027 annual shareholder meeting or the first anniversary of the grant date, contingent on continued service.
• These options represent a potential future acquisition of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard stock option grant to a director, which is a common practice and does not inherently signal positive or negative news about the company's performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The options are granted at a specific exercise price, providing a clear potential cost for future share acquisition.

Negatives

• The filing only details the acquisition of options, not the exercise of them, meaning no immediate capital infusion or share purchase has occurred.
• The vesting schedule indicates that the options are not immediately exercisable, delaying potential benefits.

Risks

• The value of the stock options is entirely dependent on the future stock price of Heartflow, Inc. If the stock price falls below $32.05, the options may not be exercised.
• Continued service is a condition for vesting, meaning any departure from the company before vesting completion would forfeit the options.

Future Outlook

The stock options acquired by the director are exercisable at $32.05 and will vest in full by the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 or the first anniversary of the grant date, subject to continued service.

Industry Context

StockSavvy.ai notes that director grants of stock options are a common form of executive compensation and incentive alignment within the biotechnology and medical device sectors, where Heartflow operates. Such grants are often tied to performance and continued employment.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of commitment, but the actual impact on share price will depend on future company performance and option exercise.
• Employees: The vesting schedule tied to continued service reinforces the importance of employee retention for option holders.
• Management: The grant aligns management's interests with those of shareholders through potential future equity gains.

Next Steps

• The stock options will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date.
• The options may be exercised by the reporting person, subject to vesting conditions and the exercise price of $32.05.

Key Dates

Keywords

Heartflow, HTFL, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Securities, Grant Date, Vesting